TempraMed Technologies Ltd. Announces Strategic Agreement with Maccabi Healthcare Services
Vancouver, British Columbia – 8 December 2025 – TempraMed Technologies Ltd. (CSE: VIVI), a Vancouver‑based medical device technology company that has pioneered the storage and management of temperature‑sensitive medications, declared today a landmark commercial partnership with Maccabi Healthcare Services, Israel’s second‑largest health maintenance organization (HMO).
A decisive step in the company’s global expansion
The agreement, announced by the company’s IRW‑Press release, places TempraMed’s flagship products, the VIVI Cap and VIVI EPI, directly into the supply chain of an HMO that serves over 2.8 million members. By integrating its innovative temperature‑control solutions into Maccabi’s distribution network, TempraMed gains immediate access to a vast market and a robust platform for further international penetration.
Why this matters
- Validation of Technology – The VIVI Cap and VIVI EPI have long been touted as industry‑leading devices that preserve the efficacy of temperature‑sensitive drugs. Their deployment within a major HMO confirms both their technical reliability and market readiness.
- Scale and Reach – Maccabi’s extensive member base provides a ready audience for TempraMed’s solutions, accelerating revenue growth and establishing a foothold in the Israeli market.
- Strategic Positioning – The partnership aligns with TempraMed’s broader expansion agenda, which seeks to bring its products to health systems worldwide. It demonstrates the company’s ability to secure deals with large, established organizations—an essential prerequisite for sustained global success.
Financial context
- Market Capitalisation: 51,404,740 CAD
- Close Price (2025‑12‑04): 0.70 CAD
- 52‑Week High: 0.96 CAD (19 October 2025)
- 52‑Week Low: 0.70 CAD (4 December 2025)
The announcement arrives as the company’s share price sits at the lower end of its recent trading range. Stakeholders will be watching closely to see whether the partnership translates into a tangible uptick in valuation and whether TempraMed can sustain the momentum needed to move beyond the Canadian market.
Conclusion
TempraMed’s strategic agreement with Maccabi Healthcare Services is not merely a contractual milestone; it is a clear signal that the company’s temperature‑management technology is finally ready to compete on an international scale. By securing a channel to a patient population of nearly three million, TempraMed has positioned itself to accelerate growth, increase revenue streams, and, most importantly, prove the commercial viability of its core innovations.
